Fulcrum Therapeutics (NASDAQ:FULC) shot up 15.9% on Tuesday . The company traded as high as $5.32 and last traded at $5.17, 421,233 shares traded hands during mid-day trading. An increase of 470% from the average session volume of 73,863 shares. The stock had previously closed at $4.46.
A number of brokerages recently weighed in on FULC. Morgan Stanley began coverage on shares of Fulcrum Therapeutics in a report on Monday, August 12th. They issued an “overweight” rating and a $29.00 price objective for the company. HC Wainwright began coverage on shares of Fulcrum Therapeutics in a report on Thursday, October 3rd. They issued a “buy” rating and a $21.00 price objective for the company. Bank of America began coverage on shares of Fulcrum Therapeutics in a report on Monday, August 12th. They issued a “buy” rating and a $19.00 price objective for the company. Svb Leerink restated an “outperform” rating on shares of Fulcrum Therapeutics in a report on Monday, August 12th. Finally, ValuEngine upgraded shares of Fulcrum Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. Five research analysts have rated the stock with a buy rating, Fulcrum Therapeutics currently has a consensus rating of “Buy” and an average target price of $23.00.
The business has a 50-day moving average of $7.80.
Fulcrum Therapeutics Company Profile (NASDAQ:FULC)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.
Featured Article: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.